A5084120719- Cardiac Valve Diseases and Treatments
- Coronary Interventions and Diagnostics
- Infective Endocarditis Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Peripheral Artery Disease Management
- Cardiac pacing and defibrillation studies
- Vascular Procedures and Complications
- Aortic Disease and Treatment Approaches
- Cardiac Imaging and Diagnostics
- Cardiovascular Function and Risk Factors
- Aortic aneurysm repair treatments
- Atrial Fibrillation Management and Outcomes
- Acute Myocardial Infarction Research
- Cardiac Arrhythmias and Treatments
- Cerebrovascular and Carotid Artery Diseases
- Mechanical Circulatory Support Devices
- Infectious Diseases and Tuberculosis
- Gastrointestinal Tumor Research and Treatment
- Cardiac Structural Anomalies and Repair
- Diagnosis and treatment of tuberculosis
- Gastric Cancer Management and Outcomes
- Tuberculosis Research and Epidemiology
- Cardiac tumors and thrombi
- Vascular Tumors and Angiosarcomas
- Biliary and Gastrointestinal Fistulas
Ascension Via Christi
2020-2025
Ascension Via Christi Hospital
2020-2025
University of Kansas
2007-2024
Valve (United States)
2022
Brigham and Women's Hospital
2021
Beth Israel Deaconess Medical Center
2021
Ascension
2021
University of Kansas Medical Center
2011-2014
Kansas City University
2013
National Institute of Cardiovascular Diseases
2010
The fourth-generation mitral transcatheter edge-to-edge repair (M-TEER) device introduced an improved clip deployment sequence, independent leaflet grasping, and 2 wider sizes to tailor the treatment of patients with regurgitation (MR) for a broad range anatomies. 30-day safety effectiveness M-TEER were previously demonstrated. aim this study was evaluate 1-year outcomes in contemporary, real-world cohort subjects treated MitraClip G4 system. EXPAND is ongoing prospective, multicenter,...
The fourth-generation MitraClip G4 System builds on the previous NTR/XTR system with additional wider clip sizes (NTW and XTW), an independent grasping feature, improved deployment sequence. primary objective of this study was to assess safety performance within a contemporary real-world setting. EXPAND is prospective, multicenter, international, single-arm, postapproval that enrolled patients (degenerative) mitral regurgitation (MR) secondary (functional) MR at 60 centers. Follow-up full...
The aim of this study was to evaluate 2 abbreviated dual-antiplatelet therapy (DAPT) regimens in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI).Current-generation drug-eluting stents are preferred over bare-metal for HBR patients, but their optimal DAPT management remains unknown.The XIENCE Short program included 3 prospective, multicenter, single-arm studies enrolling who underwent successful PCI with a cobalt-chromium everolimus-eluting stent....
The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) among patients at high bleeding risk (HBR) is unknown.The purpose this analysis was to compare 1 vs 3 months DAPT in HBR undergoing drug-eluting stent implantation.The XIENCE Short program comprised prospective, multicenter, single-arm studies treated with a short course followed by aspirin monotherapy PCI cobalt-chromium everolimus-eluting stent. In exploratory analysis, who received...
Anatomical and clinical criteria to define mitral transcatheter edge-to-edge repair (TEER) "unsuitability" have been proposed on the basis of a Heart Valve Collaboratory consensus opinion from physician experience with early-generation TEER devices but lacked an evidence-based approach.The aim this study was explore spectrum suitability using echocardiographic outcomes EXPAND G4 real-world postapproval study.EXPAND is global, prospective, multicenter, single-arm that enrolled 1,164 subjects...
Treatment of mitral regurgitation (MR) associated with severe annular calcification (MAC) is challenging due to the high risk fatal atrioventricular groove disruption and significant paravalvular leak.The aim this study was evaluate outcomes transcatheter valve replacement (TMVR) Tendyne (Abbott Structural) in patients MR MAC.Twenty (mean age 78 years; 11 women) who were treated valve, either compassionate use (CU; closed) or as part The Feasibility Study MAC (NCT03539458), had reported a...
[Figure: see text].
The Navitor transcatheter heart valve (THV) is a self-expanding valve, with an intra-annular leaflet position and outer cuff intended to reduce paravalvular leak (PVL).The aim of the PORTICO NG Study assess safety performance THV in patients symptomatic, severe aortic stenosis who are at high or extreme surgical risk.PORTICO prospective, multicentre, global, single-arm, investigational study follow-up 30 days, 1 year, annually up 5 years. primary endpoints all-cause mortality moderate...
Although extensive clinical data support the utility of intravascular imaging to guide and optimize outcomes following percutaneous coronary interventions (PCI), adoption remains limited. One primary reasons for limited utilization may be a lack standardization on how best integrate provided by practically. Optical coherence tomography (OCT) offers high-resolution modality with integrated software automation that allows incorporation OCT into routine workflow PCIs. We suggest use an...
Background.The QuantiFERON ® -TB Gold assay is a new test for latent tuberculosis infection.It thought to be more reliable and have fewer false positives than the tuberculin skin (TST).Both tests are dependent on normal immune system diagnostic accuracy.However, no comparisons of two assessed accuracy in pregnant women.This investigation consistency results between both nonpregnant women.Methods.The study included 152 women presenting care at Sedgwick County Health Department.They were...
Abstract Objectives This study was designed to compare efficiency and quality metrics between percutaneous coronary intervention (PCI) procedures using optical coherence tomography (OCT) guided by a variable workflow versus standardized in real‐world population. Background The LightLab (LL) Initiative evaluate the impact of OCT during PCI address barriers adoption. Methods LL multicenter, prospective, observational study. data were collected from 1/21/19 1/8/21 45 physicians at 17 US...
Introduction Non-occlusive mesenteric ischemia (NOMI) is an acute circulatory disorder that, in contrast to arterial occlusion induced by blockage of blood flow emboli and thrombi, not caused organic vessels. 1 Good outcomes NOMI are observed with early recognition treatment. 1-2 The symptoms characteristics NOMI, however, unclear. In many cases, the disease has advanced irreversible stage before a definite diagnosis made.